Top

04-04-2024 | Prostate Cancer

Role of Metastasis-Directed Therapy in Genitourinary Cancers

Authors: Katie N. Lee, MD, PhD, Mai Anh Huynh, MD, PhD

Published in: Current Treatment Options in Oncology

Opinion statement

The treatment of oligometastatic genitourinary cancers is a rapidly advancing field with ablative radiotherapy as one of the critical treatment components. The oligometastatic disease state, which can be defined as 1–5 metastatic sites with a controlled primary, represents a distinct clinical state where comprehensive ablative local therapies may provide improved outcomes. Enhanced imaging has increased the number of patients identified with oligometastatic disease. Evidence for improved outcomes with metastasis-directed therapy (MDT) in oligometastatic genitourinary cancers is increasing, and previously published outcome data continues to mature with an increasing body of prospective data to inform the role of MDT in histology-specific settings or in the context of systemic therapy. In select patients, MDT can offer benefits beyond improved local control and allow for time off of systemic therapy, prolonged time until next therapy, or even the hope of cure. However, treatment decisions for locally ablative therapy must be balanced with consideration towards safety. There are exciting advances in technologies to target and adapt treatment in real-time which have expanded options for safer delivery and dose escalation to metastatic targets near critical organs at risk. The role of systemic therapies in conjunction with MDT and incorporation of tumor genetic information to further refine prognostication and treatment decision-making in the oligometastatic setting is actively being investigated. These developments highlight the evolving field of treatment of oligometastatic disease. Future prospective studies combining MDT with enhanced imaging and integrating MDT with evolving systemic therapies will enable the optimal selection of patients most likely to benefit from this “all-or-none” approach and reveal settings in which a combination of therapies could result in synergistic outcomes.

•• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol [Internet]. 1995 [cited 2023 Feb 19];13(1):8–10. Available from: https://pubmed.ncbi.nlm.nih.gov/7799047/. This was the first paper to propose the theory of oligometastasis.

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020 [cited 2023 Mar 12];148:157–66. Available from: https://pubmed.ncbi.nlm.nih.gov/32388150/

Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med [Internet]. 2021 [cited 2023 Feb 28];62(5):596–604. Available from: https://pubmed.ncbi.nlm.nih.gov/33712536/

• Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol [Internet]. 2020 [cited 2023 Feb 19];21(1):e18–28. Available from: https://pubmed.ncbi.nlm.nih.gov/31908301/. This consensus guideline proposes a framework with defined criteria to sub-classify oligometastatic disease.

Thomas MC, Chen YH, Fite E, Pangilinan A, Bubelo K, Spektor A, et al. Patient and treatment factors associated with improved local control and survival in oligometastatic bone disease: results from a large single-institution experience using stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys [Internet]. 2022 [cited 2023 Mar 15];114(4):747–61. Available from: https://pubmed.ncbi.nlm.nih.gov/35840113/

Fowler JF. 21 years of biologically effective dose. Br J Radiol. 2010;83(991):554–68.CrossRefPubMedPubMedCentral

Hegemann NS, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li M. Hypofractionated radiotherapy for prostate cancer. Radiat Oncol. 2014;9(1):275.CrossRefPubMedPubMedCentral

Chetty IJ, Doemer AJ, Dolan JL, Kim JP, Cunningham JM, Dragovic J, et al. MRI-guided radiotherapy (MRgRT) for treatment of oligometastases: review of clinical applications and challenges. Int J Radiat Oncol Biol Phys [Internet]. 2022 [cited 2023 Mar 2];114(5):950–67. Available from: https://pubmed.ncbi.nlm.nih.gov/35901978/

Fleckenstein J, Petroff A, Schäfers HJ, Wehler T, Schöpe J, Rübe C. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer. BMC Cancer [Internet]. 2016 [cited 2023 Mar 2];16(1). Available from: https://pubmed.ncbi.nlm.nih.gov/27255302/

10.

Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys [Internet]. 2012 [cited 2023 Mar 2];83(3):878–86. Available from: https://pubmed.ncbi.nlm.nih.gov/22172903/

11.

Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 trial. J Clin Oncol [Internet]. 2019 [cited 2023 Mar 2];37(15):1316–25. Available from: https://pubmed.ncbi.nlm.nih.gov/30943123/

12.

Romesser PB, Tyagi N, Crane CH. Magnetic resonance imaging-guided adaptive radiotherapy for colorectal liver metastases. Cancers (Basel) [Internet]. 2021 [cited 2023 Mar 2];13(7). Available from: https://pubmed.ncbi.nlm.nih.gov/33915810/

13.

Rosenberg SA, Henke LE, Shaverdian N, Mittauer K, Wojcieszynski AP, Hullett CR, et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Adv Radiat Oncol [Internet]. 2018 [cited 2023 Mar 2];4(1):142–9. Available from: https://pubmed.ncbi.nlm.nih.gov/30706022/

14.

Borghesi S, Casamassima F, Aristei C, Grandinetti A, di Franco R. Stereotactic radiotherapy for adrenal oligometastases. Rep Pract Oncol Radiother [Internet]. 2022 [cited 2023 Mar 2];27(1):52–6. Available from: https://pubmed.ncbi.nlm.nih.gov/35402020/

15.

de Ruysscher D, Wanders R, Hendriks LE, van Baardwijk A, Reymen B, Houben R, et al. Progression-free survival and overall survival beyond 5 years of nsclc patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450). J Thorac Oncol [Internet]. 2018 [cited 2023 Mar 2];13(12):1958–61. Available from: https://pubmed.ncbi.nlm.nih.gov/30253974/

16.

Chmura S, Winter KA, Robinson C, Pisansky TM, Borges V, Al-Hallaq H, et al. Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 phase 1 trial. JAMA Oncol [Internet]. 2021 [cited 2023 Mar 2];7(6):845–52. Available from: https://pubmed.ncbi.nlm.nih.gov/33885704/

17.

Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, et al. Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers. Eur Urol Oncol [Internet]. 2023 [cited 2023 Mar 2];6(1). Available from: https://pubmed.ncbi.nlm.nih.gov/36283936/

18.

Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021;22(7):1023–33.CrossRefPubMed

19.

Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 2019;5(6):872–8.CrossRefPubMedPubMedCentral

20.

•• Palma DA, Olson R, Harrow S, Gaede S, Louie A V., Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet [Internet]. 2019 18 [cited 2023 Mar 2];393(10185):2051–8. Available from: https://pubmed.ncbi.nlm.nih.gov/30982687/. This was the first Phase 2 randomized controlled trial to demonstrate a clinical benefit to metastatic-directed therapy for patients with extracranial oligometastatic disease.

21.

Palma DA, Olson R, Harrow S, Gaede S, Louie A v., Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II randomized trial. J Clin Oncol. 2020;38(25):2830–8.

22.

Liu W, Bahig H, Palma DA. Oligometastases: emerging evidence. J Clin Oncol [Internet]. 2022 [cited 2023 Feb 28];40(36):4250–60. Available from: https://pubmed.ncbi.nlm.nih.gov/36306497/

23.

•• Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, DeBruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol [Internet]. 2018 [cited 2023 Feb 28];36(5):446–53. Available from: https://pubmed.ncbi.nlm.nih.gov/29240541/. This was the first randomized Phase 2 trial to show a clinical benefit of metastatic-directed therapy for oligorecurrent prostate cancer.

24.

•• Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol [Internet]. 2020 [cited 2023 Feb 28];6(5):650. Available from: /pmc/articles/PMC7225913/. This was the second randomized Phase 2 trial to show a clinical benefit of metastatic-directed therapy for oligorecurrent prostate cancer.

25.

Brennan V, Spektor A, Sweeney C, Choudhury A, Rathkopf D, Pomerantz M, et al. Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for oligometastatic prostate cancer. Adv Radiat Oncol. 2022;7(1): 100808.CrossRefPubMed

26.

• Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41(36):5561–8. This study (presented in abstract form) is the first randomized Phase 2 trial to show a benefit of metastatic-directed therapy for oligometastatic castrate-resistant prostate cancer.

27.

Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol [Internet]. 2012 [cited 2023 Mar 2];23(4):973–80. Available from: https://pubmed.ncbi.nlm.nih.gov/21890909/

28.

• Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol [Internet]. 2021 [cited 2023 Mar 13];22(12):1732–9. Available from: https://pubmed.ncbi.nlm.nih.gov/34717797/. This study was a prospective Phase 2 trial demonstrating the benefit of SBRT in delaying time to next therapy for patients with oligometastatic renal cell cancer.

29.

• Hannan R, Christensen M, Christie A, Garant A, Pedrosa I, Robles L, et al. Stereotactic ablative radiation for systemic therapy-naïve oligometastatic kidney cancer. Eur Urol Oncol [Internet]. 2022 [cited 2023 Mar 2];5(6):695–703. Available from: https://pubmed.ncbi.nlm.nih.gov/35985982/. This study was a prospective Phase 2 trial demonstrating the benefit of SBRT in delaying time to next therapy for patients with oligometastatic renal cell cancer.

30.

Heinzerling JH, Hampton CJ, Robinson M, Bright M, Moeller BJ, Ruiz J, et al. Use of surface-guided radiation therapy in combination with IGRT for setup and intrafraction motion monitoring during stereotactic body radiation therapy treatments of the lung and abdomen. J Appl Clin Med Phys. 2020;21(5):48–55.CrossRefPubMedPubMedCentral

31.

Zhou AZ, Conway L, Bartlett S, Marques A, Physic M, Czerminska M, et al. Prospective evaluation of the clinical benefits of a novel tattoo-less workflow for non-spine bone Stereotactic Body Radiation Therapy (SBRT): integrating surface-guidance with triggered imaging reduces treatment time and eliminates the need for tattoos. Pract Radiat Oncol. 2023.

32.

Hu DY, Xu Y, Chen YH, Khosravi M, Lyatskaya Y, Bredfeldt JS, et al. Less time is less motion: analysis of practical efficiencies gained with a modified workflow integrating planar kV midimaging with CBCT for spine stereotactic body radiation therapy. Adv Radiat Oncol. 2022;7(5): 100961.CrossRefPubMedPubMedCentral

33.

Yang DD, Brennan VS, Huynh E, Williams CL, Han Z, Ampofo N, et al. Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for abdominopelvic oligometastases. Int J Radiat Oncol Biol Phys [Internet]. 2022 [cited 2023 Feb 28];114(5):941–9. Available from: https://pubmed.ncbi.nlm.nih.gov/35598799/

34.

Janssen TM, Aitken K, Alongi F, Barry A, Bernchou U, Boeke S, et al. First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. Tech Innov Patient Support Radiat Oncol [Internet]. 2022 [cited 2023 Feb 28];22:50–4. Available from: https://pubmed.ncbi.nlm.nih.gov/35586786/

35.

Nicosia L, Trapani G, Rigo M, Giaj-Levra N, Mazzola R, Pastorello E, et al. 1.5 T MR-guided daily adapted SBRT on lymph node oligometastases from prostate cancer. J Clin Med [Internet]. 2022 [cited 2023 Mar 12];11(22). Available from: https://pubmed.ncbi.nlm.nih.gov/36431135/

36.

Mancosu P, Lambri N, Castiglioni I, Dei D, Iori M, Loiacono D, et al. Applications of artificial intelligence in stereotactic body radiation therapy. Phys Med Biol [Internet]. 2022 [cited 2023 Oct 30];67(16). Available from: https://pubmed.ncbi.nlm.nih.gov/35785778/

37.

Yamamoto T, Niibe Y, Aoki M, Shintani T, Yamada K, Kobayashi M, et al. Analyses of the local control of pulmonary oligometastases after stereotactic body radiotherapy and the impact of local control on survival. BMC Cancer [Internet]. 2020 [cited 2023 Mar 2];20(1). Available from: https://pubmed.ncbi.nlm.nih.gov/33054721/

38.

Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol [Internet]. 2015 [cited 2023 Mar 2];114(2):155–60. Available from: https://pubmed.ncbi.nlm.nih.gov/25583567/

39.

Deek MP, Van Der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol [Internet]. 2022 [cited 2023 Oct 31];40(29):3377–82. Available from: https://pubmed.ncbi.nlm.nih.gov/36001857/

40.

Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw [Internet]. 2023 [cited 2023 Oct 31];21(10):1067–96. Available from: https://pubmed.ncbi.nlm.nih.gov/37856213/

41.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.CrossRefPubMedPubMedCentral

42.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700.CrossRefPubMed

43.

Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616–22.CrossRefPubMedPubMedCentral

44.

Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021 39(20):2294–303.

45.

Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323–34.CrossRefPubMed

46.

Freedland SJ, de Almeida LM, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453–65.CrossRefPubMed

47.

• Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol [Internet]. 2023 [cited 2023 Oct 31];9(6):825–34. Available from: https://pubmed.ncbi.nlm.nih.gov/37022702/. This study was the first prospective phase 2 randomized study to report on outcomes of metastatic-directed therapy for prostate cancer in the context of hormone therapy.

48.

Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial. Eur Urol [Internet]. 2022 [cited 2023 Oct 31];81(4):364–72. Available from: https://pubmed.ncbi.nlm.nih.gov/34953600/

49.

Moore C, Hsu CC, Chen WM, Chen BPC, Han C, Story M, et al. Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade. Int J Radiat Oncol Biol Phys. 2021;110(5):1306–16.CrossRefPubMedPubMedCentral

50.

Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol [Internet]. 2023 [cited 2023 Oct 31];24(3):e121–32. Available from: https://pubmed.ncbi.nlm.nih.gov/36858728/

Title: Role of Metastasis-Directed Therapy in Genitourinary Cancers
Authors: Katie N. Lee, MD, PhD
Mai Anh Huynh, MD, PhD
Publication date: 04-04-2024
Publisher: Springer US
Keywords: Prostate Cancer
Prostate Cancer
Metastasis
Systemic Therapy
Published in: Current Treatment Options in Oncology
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-024-01199-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Opinion statement

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer